Literature DB >> 22935748

Low-grade myofibroblastic sarcoma of the palate.

Tomohiro Yamada1, Tomohide Yoshimura, Naoya Kitamura, Eri Sasabe, Seiji Ohno, Tetsuya Yamamoto.   

Abstract

Low-grade myofibroblastic sarcoma (LGMS) is a rare, malignant tumor with myofibroblastic differentiation. Despite it being classified as a distinct entity by the World Health Organization, a few cases were reported in the oral and maxillofacial region. Here, a LGMS developed on the palate of a 73-year-old man who presented with a 1-cm tumor on the posterior border of the palate. Based on the histological and immunohistochemical features, a diagnosis of LGMS was established. The tumor was resected, and no recurrence was observed over 2 years. Although the tongue is the most preferred site for LGMS, it may occur in any region of the oral cavity.

Entities:  

Mesh:

Year:  2012        PMID: 22935748      PMCID: PMC3465011          DOI: 10.1038/ijos.2012.49

Source DB:  PubMed          Journal:  Int J Oral Sci        ISSN: 1674-2818            Impact factor:   6.344


Introduction

Myofibroblasts are derived from fibroblasts, and exist in various tissues such as normal connective tissues, granulation tissue and reactives inflammatory tissues.[1] Occasionally, myofibroblasts undergo tumorgenic transformation and become malignant.[2] A low-grade myofibroblastic sarcoma (LGMS) is a rare malignant tumor with myofibroblastic differentiation, and just a few cases have been reported in the oral and maxillofacial region.[3] Here, we describe a patient with LGMS of the palate, and bibliographic considerations are reviewed.

Case report

A 73-year-old man was referred by his general dental practitioner to the Department of Oral and Maxillofacial Surgery (Kochi University, Kochi, Japan) regarding a tumor on the palate that had developed over a couple of months. There was no associated pain, or paraesthesia. A systematic examination revealed a fit and healthy man. His medical histories included a gastric ulcer, prostatic hyperplasia and cervical spondylotic radiculopathy. Physical examination revealed an elastic hard, 10 mm×10 mm mass on the posterior border of the palate. The mass was fixed to the underlying tissues with distinct margins. The surface mucosa was slightly reddish and irregular (Figure 1). An excisional biopsy of the palatal mass was performed, and microscopic examination revealed infiltrative spindle tumor cells surrounded by a fibrous capsule. The tumor cells were dense in some parts but sparse in other areas. The tumor cells had round-shaped or spindle nuclei, and the cytoplasm was eosinophilic. There were few mitotic cells, however, and atypical cells with large nuclei were observed (Figure 2).
Figure 1

Intraoral photo at the initial visit. An elastic, hard, 10 mm×10 mm mass is seen on the posterior border of the palate.

Figure 2

Histology of the tumor. The tumor cells had round-shaped or spindle nuclei, and the cytoplasm was eosinophilic. Mitotic cells were sparse, and atypical cells with large nuclei were observed. Hematoxylin and eosin staining, a: ×40; b: ×200.

Immunohistochemistry revealed that most spindle cells were immunoreactive for muscle-specific actin (HHF35), and focally for α-smooth muscle actin (α-SMA) and MIB-1 (Figure 3), in contrast, immunostaining for other markers, such as CD34, CD68, desmin, epithelial membrane antigen (EMA), S-100 protein, cytokeratin (AE1/AE3), and p53 was not observed (Table 1). The patient was therefore diagnosed with LGMS. The surgical sample margins appeared to be tumor-free upon histological analysis. The patient was disease-free at the last examination, 2 years postoperatively (Figure 4).
Figure 3

Immunohistochemical staining of the tumor. The spindle cells were focally immunoreactive for α-SMA (a: ×200) and MIB-1 (b: ×200). α-SMA, α-smooth muscle actin.

Table 1

Immunohistochemical findings

MarkersImmunoreactivity
α-SMA+
Muscle-specific actin+
EMA
S-100
AE1/AE3
CD34
MIB-1 LI10%

EMA, epithelial membrane antigen; α-SMA, α-smooth muscle actin.

Immunohistochemistry revealed that most spindle cells were immunoreactive for muscle specific actin, and focally for α-SMA and MIB-1, whereas immunostaining for other markers such as EMA, S-100 protein, cytokeratin (AE1/AE3) and CD34 was not observed.

Figure 4

Intraoral photo 2 years after removal of the tumor. There is only scar on the posterior border of the palate, and no reoccurrence was observed.

Discussion

Myofibroblasts are mesenchymal spindle cells that are first observed in the granulation tissue of healing wounds, and play a role in the production of contractile force.[1] Myofibroblasts exist under various reactive conditions, including reparative granulation tissue, granulomas, inflammatory pseudotumors, and various benign and malignant soft tissue tumors.[4] LGMS used to be a controversial neoplasm, but has been reclassified as a distinct entity in the newly published World Health Organization classification of soft tissue tumors.[2] However, intermediate- and high-grade myofibroblastic sarcomas were also documented in the literature.[5,6,7] High-grade (pleomorphic) myofibroblastic sarcomas were described as pleomorphic sarcomas composed of atypical spindle, polygonal and giant cells showing the ultrastructural features of myofibroblastic differentiation and numerous mitotic figures.[8] Histologically, LGMS is composed of slender spindle cells arranged in interlacing fascicles. The tumor cells have a scanty to moderate amount of eosinophilic or amphophilic cytoplasm and fusiform nuclei with mild nuclear pleomorphism and a low mitotic rate. Immunohistochemically, myofibroblastic sarcoma is immunopositive for vimentin, SMA, muscle-specific actin, calponin and fibronectin, rarely immunopositive for desmin, and immunonegative for laminin and type IV collagen.[3,9] Furthermore, LGMS are no immunoreactive for s-100, EMA, cytokeratin or CD34.[10] LGMS is easily confused with myofibroblasts composed of nodular fasciitis because of their morphological similarity and overlapping immunophenotype.[11] However, unlike myofibroblastic sarcoma, the appearance is not monomorphic.[12] In addition to nodular fasciitis, LGMS is differentiated from leiomyosarcoma, malignant fibrous histiocytoma, inflammatory myofibroblastic tumor and fibromatosis. Leiomyosarcoma has a well-delineated pushing margin and show longitudinally fibrillary cytoplasm and cigar-shaped vesicular nuclei with paranuclear vacuolation.[7] Malignant fibrous histiocytoma shows anaplasia and multinucleated giant cells and marked cytological pleomorphism and nuclear atypia.[7] Inflammatory myofibroblastic tumor is composed of myofibroblast and fibroblasts with inflammatory cell infiltration.[7] Fibromatosis is characterized by fibroblasts and myofibroblasts in parallel alignment, but cytologic atypia and nuclear pleomorphism are absent.[10] The specimen from our case was immunopositive for SMA and muscle-specific actin, and was immunonegative for EMA, s-100, AE1/AE3 and CD34. Histologically, infiltrative spindle tumor cells showed a myofibroblastic differentiation, and there were several atypical cells. Based on these findings, it was diagnosed as a LGMS. LGMS mainly occurs in adults, and most frequently affects the deep soft tissues of the oral cavity (especially the tongue), limbs, trunk, or abdominal and pelvic cavities.[2,13] The head and neck region, including the oral cavity, is the preferred location for LGMS; however, only few cases were reported of LGMS occurring in the oral and maxillofacial region.[10] In the literature, there are 38 cases of LGMS in the oro-maxillofacial region, including our case (Table 2). The average age was 40.7 years (range: 2–85 years, median: 41 years), and the male to female ratio was 4∶3. The tongue was the most preferred site, followed by the maxilla and palate, mandible, nasal/paranasal cavity and deep tissue spaces including the parapharyngeal space. Our patient is the third case occurring in the palate.
Table 2

LGMS in the oral and maxillofacial region

CaseReferenceGenderAge/yearSiteSize/cmTreatmentReoccurrence
116M75ParietalNANAY
216M85FaceNANAN
317F43Face1.5NAN
418F12Maxilla6.0NAY
518M18MaxillaNANAY
618F9MandibleNANAY
718F13TonsilNANAN
818F9MandibleNANAN
99F51Tongue2.5Local excisionN
109M70Tongue1.4Local excisionN
119M24Tongue1.5Local excisionN
129M66Tongue1.8Wide excisionN
139M19Mandible3.5Local excision, RT, CTN
1419F71Parotid gland1.7Wide excisionN
155M24Maxillary sinus4.0Wide excisionN
165M49Maxilla8.0Wide excisionY
173M41Hard palate3.5Wide excisionN
183M35Palate1.6Local excisionY
193F54Gingiva1.5Local excisionY
2020F77Nasal cavity3.0Local excisionY
2114F8Pterygoid region6.0Wide excision, CTN
2214F2Temporal fossa2.9Wide excisionN
2321F37Cheek2.0Wide excisionN
2422F24Tongue2.0Local excisionN
2523M42Parapharyngeal spaceNART, CTY (dead)
2612M41Tongue1.7Local excisionY
2724M28Lower lip2.0local excisionNA
287M74Nasal cavity3.0NAY
297M14Ethmoid sinus4.5NAY
307M14Nasal cavity5.0NAY
3110M51Mandible3.0Wide excisionN
3210F61Tongue4.0Wide excisionN
334F56Tongue base2.0Local excision, RTN
3415M54Mandible6.0Local excisionN
35current caseM73Palate1.0Local excisionN

CT, chemotherapy; RT, radiotherapy.

The recurrence rate (RR) was 38.2%, including one fatal case. RR was the highest when tumor is sited in nasal cavity/paranasal sinus. Second is jawbone, followed by deep tissue space (Table 3). RR was 21.4% when tumor size was less than 3 cm, whereas that of over 3-cm tumor was 46.2%. As LGMS is associated with little symptoms, early detection may be difficult when tumors are in deep tissues, such as nasal cavity, paranasal sinus, jawbone and masticatory space, resulting high RR.
Table 3

Reoccurrence and tumor site

SiteReoccurrence cases/total casesreoccurrence rate/%
Tongue1/812.5
Jaw (incl. gingiva)5/955.5
Nasal cavity/paranasal sinus4/580.0
Palate1/333.3
Deep tissue space2/450.0
Others0/50.0
Total13/3438.2

Reoccurrence rate is the highest when tumor is sited in nasal cavity/paranasal sinus. Second is jawbone, followed by deep tissue space.

LGMS may cause focal recurrences and metastasis, and it has a relatively indolent course.[7,14] It tends to recur locally rather than to metastasize.[15] Radiotherapy or chemotherapy are not established treatments, and the importance of surgery is emphasized.[14] Our case showed no recurrence 2 years postoperatively, but further observation is required.
  23 in total

Review 1.  Myofibroblasts and mechano-regulation of connective tissue remodelling.

Authors:  James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown
Journal:  Nat Rev Mol Cell Biol       Date:  2002-05       Impact factor: 94.444

2.  Myofibrosarcoma of the nasal cavity and paranasal sinus.

Authors:  S Kondo; T Yoshizaki; H Minato; I Horikawa; A Tatsumi; M Furukawa
Journal:  Histopathology       Date:  2001-08       Impact factor: 5.087

3.  Low-grade myofibrosarcoma of the head and neck: importance of surgical therapy.

Authors:  Charles Keller; Callie N Gibbs; Steven M Kelly; Jeffrey R Haller; Keith S White; Cheryl M Coffin; Richard S Lemons
Journal:  J Pediatr Hematol Oncol       Date:  2004-02       Impact factor: 1.289

4.  Myofibrosarcoma of subcutaneous soft tissue of the cheek.

Authors:  B P Eyden; L Christensen; V Tagore; M Harris
Journal:  J Submicrosc Cytol Pathol       Date:  1992-07

5.  Myofibroblastic tumor of the lower lip in a patient with X-linked hypogammaglobulinemia and isolated growth hormone deficiency: a case report.

Authors:  Matin M Imanguli; Laszlo J Karai; Rabie M Shanti; Donn M Stewart; Jaime S Brahim
Journal:  J Oral Maxillofac Surg       Date:  2007-06       Impact factor: 1.895

6.  Myofibrosarcoma of the upper jawbones: a clinicopathologic and ultrastructural study of two cases.

Authors:  M Bisceglia; N Tricarico; P Minenna; G Magro; G Pasquinelli
Journal:  Ultrastruct Pathol       Date:  2001 Sep-Oct       Impact factor: 1.094

7.  Myofibroblastic sarcomas: a clinicopathological study of 20 cases.

Authors:  Guo-zhao Meng; Hong-ying Zhang; Hong Bu; Xian-liang Zhang; Zong-guo Pang; Qi Ke; Xi Liu; Guo Yang
Journal:  Chin Med J (Engl)       Date:  2007-03-05       Impact factor: 2.628

8.  Low grade myofibroblastic sarcoma of tongue: a case report.

Authors:  J Laco; E Simáková; R Slezák; L Tucek; R Mottl; J Spacek; A Ryska
Journal:  Cesk Patol       Date:  2006-07

9.  Myofibrosarcoma: a clinicopathologic study.

Authors:  E Montgomery; J R Goldblum; C Fisher
Journal:  Am J Surg Pathol       Date:  2001-02       Impact factor: 6.394

10.  Low-grade myofibroblastic sarcoma of the mandible: a case report.

Authors:  Iwona Niedzielska; Tomasz Janic; Bartlomiej Mrowiec
Journal:  J Med Case Rep       Date:  2009-08-10
View more
  13 in total

1.  Low-grade myofibroblastic sarcoma arising in the tip of the tongue with intravascular invasion: A case report.

Authors:  Yurie Mikami; Shinsuke Fujii; Ken-Ichi Kohashi; Yuichi Yamada; Masafumi Moriyama; Shintaro Kawano; Seiji Nakamura; Yoshinao Oda; Tamotsu Kiyoshima
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

2.  Low-grade myofibroblastic sarcomas of the maxilla.

Authors:  Jin-Yu Qiu; Peng Liu; Ce Shi; Bing Han
Journal:  Oncol Lett       Date:  2014-12-11       Impact factor: 2.967

3.  Giant low-grade primary myofibroblastic sarcoma of the posterior chest wall.

Authors:  Darko Katalinic; Fedor Santek
Journal:  World J Surg Oncol       Date:  2017-05-03       Impact factor: 2.754

4.  Indolent growth of low-grade myofibroblastic sarcoma of the cheek mimics benign lesions: A case report and literature review.

Authors:  Tessho Maruyama; Toshiyuki Nakasone; Fumikazu Nimura; Akira Matayoshi; Toshihiro Kawano; Kazuhide Nishihara; Akira Arasaki
Journal:  Oncol Lett       Date:  2017-04-10       Impact factor: 2.967

5.  Low-grade Myofibroblastic sarcoma: clinical and imaging findings.

Authors:  Lu Wang; Ling-Xia Li; De-Qiang Chen; Lin Yang; Shu-Kui Li; Cai Cheng
Journal:  BMC Med Imaging       Date:  2019-05-02       Impact factor: 1.930

Review 6.  Low-grade myofibroblastic sarcoma of the levator scapulae muscle: a case report and literature review.

Authors:  Hirotaka Yonezawa; Norio Yamamoto; Katsuhiro Hayashi; Akihiko Takeuchi; Shinji Miwa; Kentaro Igarashi; Mickhael Bang Langit; Hiroaki Kimura; Shingo Shimozaki; Takashi Kato; Sei Morinaga; Yoshihiro Araki; Yohei Asano; Hiroko Ikeda; Takayuki Nojima; Hiroyuki Tsuchiya
Journal:  BMC Musculoskelet Disord       Date:  2020-12-10       Impact factor: 2.362

7.  Sarcomas of the Larynx: One Institution's Experience and Treatment Protocol Analyses.

Authors:  Jaromir Astl; Richard Holy; Inna Tuckova; Tomas Belsan; Miloslav Pala; Jan Rotnagl
Journal:  Medicina (Kaunas)       Date:  2021-02-25       Impact factor: 2.430

8.  Low-Grade Myofibroblastic Sarcoma of the Oral Cavity: A Report of Three Cases Illustrating an Emerging Disease in Children.

Authors:  Primali Rukmal Jayasooriya; Chamara Athukorala; Manjula Attygalla; Balapuwaduge Ranjit Rigobert Nihal Mendis; Tommaso Lombardi
Journal:  Dermatopathology (Basel)       Date:  2021-01-01

Review 9.  Myofibroblasts: Master of disguise.

Authors:  Bhavana S Bagalad; K P Mohan Kumar; H K Puneeth
Journal:  J Oral Maxillofac Pathol       Date:  2017 Sep-Dec

Review 10.  Low-grade myofibroblastic sarcoma of the orbit: A case report and literature review.

Authors:  Shikun Zhang; Ying Ma; Tie Ma; Zhiming Wang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.